ST Pharm
ST Pharm
01
Who we are
02
Our record
03
Newsroom
04
Contact
En
Ko
ST Pharm
Science & Technology
Business Overview
CDMO
Small Molecule
Oligonucleotide
mRNA
CRO
AnaPath Research & Service
R&D
Virtual R&D
Global R&D
About
ST PHARM
Key Members
History
Global Approval
ST Pharm Family
CI
Public
PR (Public Relations)
News room
All
Media Focus
ST PHARM News
IR (Investor Relations)
Stock Information
IR Library
Disclosure Information
IR Materials
Notice
Careers
ESG
Overview
Environmental
Social
Governance
Sitemap
Contact
Linkedin
Public
IR Materials
PR (Public Relations)
News room
All
Media Focus
ST PHARM News
IR (Investor Relations)
Stock Information
IR Library
Disclosure Information
IR Materials
Notice
IR Library
Disclosure Information
IR Materials
Notice
[Presentation] ST PHARM mRNA platform
May 20, 2022
[Presentation] ST PHARM IR Presentation (April 2022)
May 9, 2022
[Analyst Report] Focus on where it is headed, not where it is now
Apr 29, 2022
[Analyst Report] Bags major oligonucleotide drug deal
Mar 21, 2022
[Analyst Report] Slips to operating loss due to costs, deferred oligo sales
Feb 28, 2022
[Analyst Report] Aggressive capex to cement position as global CMO
Dec 2, 2021
[Analyst Report] Growing oligo sales proven to boost profits
Oct 29, 2021
[Analyst Report] Developing a COVID-19 mRNA vaccine
Jul 23, 2021
2
of
2